Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system

blonca9
Sep 5, 2024
1 min read

CEO Pierre Belichard describes the scientific underpinnings of this idea, and how it has lead to Enterome's programs, including one in NHL that has caught the attention of the Leukemia & Lymphoma Society and will have data around ASH time.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight